Katherine Hendy: The Placebo Paradox

Psychedelic clinical research faces a distinct challenge regarding the use of double-blind, placebo-controlled trials. Establishing a placebo that effectively masks MDMA and other psychoactive substances requires a nuanced strategy that accounts for the subjective nature of the therapeutic experience and the rigorous demands of institutional regulatory standards. Historically, the institutionalization of double-blind protocols emerged as a primary requirement for drug approval, often creating tension between these bureaucratic standards and the lived experience of study participants. Katherine Hendy addresses how the struggle to implement such blind tests reveals broader insights into the complexities of clinical research and the necessity of reconciling objective data with the subjective realities inherent in psychedelic medicine.